Cryptome completes acquisition of HealthLinx
Cryptome Pharmaceuticals Limited announced that it has completed the acquisition of HealthLinx Pty Ltd. HealthLinx, a privately held company before its acquisition, focuses on biomarkers and the development of diagnostics, with its lead candidates targeting ovarian cancer and complications in pregnancy. This follows the approval by shareholders of the transaction at the extraordinary general meeting.
The all-scrip acquisition has been accompanied by a capital raising of $2 million, which provides a strong funding base for the business, alongside revenue to be generated by the previously announced Dairy Australia contract. The merged entity will be known as HealthLinx Limited (HealthLinx). A new ASX code will be allocated and advised shortly.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.